Published in Hepatitis Weekly, October 24th, 2005
Researchers in France conducted a study "to evaluate the incidence, clinical features, and risk factors for symptomatic mitochondrial toxicity in HIV/(HCV)-coinfected patients receiving anti-HCV therapy. All cases of symptomatic mitochondrial toxicity reported in 416 patients participating in an open, randomized trial of peg-interferon alpha-2b plus ribavirin vs. interferon alpha-2b plus ribavirin for 48 weeks were reviewed."
"Associations with antiretroviral treatments and with clinical and laboratory findings were sought by univariate and multivariate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly